Clinical Scorecard: Efficacy of Sublingual Cyclobenzaprine for Pain Management in Fibromyalgia: Results from a Phase 3 Randomized Controlled Trial Focusing on Nonrestorative Sleep
At a Glance
Category
Detail
Condition
Fibromyalgia, a nociplastic chronic pain syndrome characterized by widespread pain, nonrestorative sleep, and fatigue
Key Mechanisms
Nociplastic pain involving central and peripheral sensitization; targeting disturbed sleep to improve symptoms
Target Population
Adults with fibromyalgia, predominantly women, experiencing widespread pain, disrupted sleep, and fatigue
TNX-102 SL (sublingual cyclobenzaprine) 5.6 mg taken at bedtime significantly reduced pain intensity compared to placebo over 14 weeks
Treatment improved core fibromyalgia symptoms including pain, sleep disturbance, fatigue, and overall function
TNX-102 SL was generally safe and well tolerated; most common adverse events were mild, transient oral administration-site reactions
Guideline-Based Recommendations
Diagnosis
Diagnosis based on clinical features of widespread pain, nonrestorative sleep, and fatigue consistent with fibromyalgia
Management
Consider bedtime TNX-102 SL 5.6 mg for fibromyalgia patients with significant pain and sleep disturbance
Pharmacologic targeting of disturbed sleep may improve pain and fatigue symptoms
Monitor for local oral adverse events associated with sublingual administration
Monitoring & Follow-up
Assess weekly average daily pain intensity scores
Evaluate patient global impression of change and fibromyalgia impact on symptoms and function
Monitor sleep quality and fatigue using validated patient-reported outcome measures
Observe for treatment-emergent adverse events, especially oral hypoesthesia, taste abnormalities, and paresthesia
Risks
Potential for mild, transient oral administration-site reactions such as oral hypoesthesia, taste abnormality, and oral paresthesia
Systemic adverse events including headache and somnolence occurred but were less common
No significant safety concerns beyond known side effects of cyclobenzaprine observed
Patient & Prescribing Data
Adults with fibromyalgia experiencing widespread pain, nonrestorative sleep, and fatigue
Once-nightly TNX-102 SL 5.6 mg after initial 2-week titration from 2.8 mg demonstrated significant symptom improvement and was well tolerated with high trial completion rates
Clinical Best Practices
Initiate TNX-102 SL at 2.8 mg nightly for 2 weeks before increasing to 5.6 mg to improve tolerability
Administer TNX-102 SL at bedtime to align peak drug levels with sleep phase
Use validated patient-reported outcome measures to monitor efficacy on pain, sleep, fatigue, and function
Educate patients about possible mild oral side effects that are typically transient and self-limited
Consider TNX-102 SL as an option to reduce polypharmacy and improve multiple fibromyalgia symptoms simultaneously
